Cryptococcosis

Essentials of Clinical Mycology: Second Edition

Volumn , Issue , 2011, Pages 207-226

  Baddley, John W ^a   Dismukes, William E ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84880928393     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-6640-7_12     Document Type: Chapter

References (187)

1. de Hoog G. Atlas of Clinical Fungi. 2nd ed. Washington, DC: American Society for Microbiology Press; 2001.
2. Johnson LB, Bradley SF, Kauffman CA. Fungaemia due to Cryptococcus laurentii and a review of non-neoformans cryptococcaemia. Mycoses. 1998;41:277-80.
3. Khawcharoenporn T, Apisarnthanarak A, Mundy LM. Nonneoformans cryptococcal infections: A systematic review. Infection. 2007;35:51-8.
4. Kordossis T, Avlami A, Velegraki A, et al. First report of Cryptococcus laurentii meningitis and a fatal case of Cryptococcus albidus cryptococcaemia in AIDS patients. Med Mycol. 1998;36:335-9.
5. Neilson JB, Fromtling RA, Bulmer GS. Cryptococcus neoformans: Size range of infectious particles from aerosolized soil. Infect Immun. 1977;17:634-8.
6. Franzot SP, Salkin IF, Casadevall A. Cryptococcus neoformans var. grubii: Separate varietal status for Cryptococcus neoformans serotype A isolates. J Clin Microbiol. 1999;37:838-40.
7. Kidd SE, Hagen F, Tscharke RL, et al. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci USA. 2004;101:17258-63.
8. Chambers C, MacDougall L, Li M, Galanis E. Tourism and specific risk areas for Cryptococcus gattii, Vancouver Island, Canada. Emerg Infect Dis. 2008;14:1781-3.
9. Byrnes 3rd EJ, Bildfell RJ, Frank SA, Mitchell TG, Marr KA, Heitman J. Molecular evidence that the range of the Vancouver Island outbreak of Cryptococcus gattii infection has expanded into the Pacific Northwest in the United States. J Infect Dis. 2009; 199:1081-6.
10. Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev. 1995;8:515-48.
11. Kwon-Chung KJ, Bennett JE. Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am J Epidemiol. 1984;120:123-30.
12. Kwon-Chung KJ. A new species of Filobasidiella, the sexual state of Cryptococcus neoformans B and C serotypes. Mycologia. 1976; 68:943-6.
13. Min KH, Kwon-Chung KJ. The biochemical basis for the distinction between the two Cryptococcus neoformans varieties with CGB medium. Zbl Bakt Mik Hyg. 1986;261:471-80.
14. Levitz SM. The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis. Rev Infect Dis. 1991;13:1163-9.
15. Emmons CW. Saprophytic sources of Cryptococcus neoformans associated with the pigeon (Columba livia). Am J Hyg. 1955;62: 227-32.
16. Girish Kumar KCP, Prabu D, Mitani H, Mikami Y, Menon T. Environmental isolation of Cryptococcus neoformans and Cryptococcus gattii from living trees in Guindy National Park, Chennai, South India. Mycoses. 2010;53:262-4.
17. Refojo N, Perrotta D, Brudny M, Abrantes R, Hevia AI, Davel G. Isolation of Cryptococcus neoformans and Cryptococcus gattii from trunk hollows of living trees in Buenos Aires City, Argentina. Med Mycol. 2009;47:177-84.
18. Granados DP, Castaneda E. Isolation and characterization of Cryptococcus neoformans varieties recovered from natural sources in Bogota, Colombia, and study of ecological conditions in the area. Microb Ecol. 2005;49:282-90.
19. Ellis DH, Pfeiffer TJ. Natural habitat of Cryptococcus neoformans var. gattii. J Clin Microbiol. 1990;28:1642-4.
20. Chen SC, Currie BJ, Campbell HM, et al. Cryptococcus neoformans var. gattii infection in northern Australia: existence of an environmental source other than known host eucalypts. Trans R Soc Trop Med Hyg. 1997;91:547-50.
21. Fink JN, Barboriak JJ, Kaufman L. Cryptococcal antibodies in pigeon breeders' disease. J Allergy. 1968;41:297-301.
22. Newberry Jr. WM, Walter JE, Chandler Jr. JW, Tosh FE. Epidemiologic study of Cryptococcus neoformans. Ann Intern Med. 1967;67:724-32.
23. Hajjeh RA, Conn LA, Stephens DS, Cryptococcal Active Surveillance Group, et al. Cryptococcosis: Population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. J Infect Dis. 1999;179:449-54.
24. Powell KE, Dahl BA, Weeks RJ, Tosh FE. Airborne Cryptococcus neo formans: Particles from pigeon excreta compatible with alveolar deposition. J Infect Dis. 1972;125:412-5.
25. Swinne D, Deppner M, Laroche R, Floch JJ, Kadende P. Isolation of Cryptococcus neoformans from houses of AIDS-associated cryptococcosis patients in Bujumbura (Burundi). AIDS (London). 1989;3:389-90.
26. Duperval R, Hermans PE, Brewer NS, Roberts GD. Cryptococcosis, with emphasis on the significance of isolation of Cryptococcus neoformans from the respiratory tract. Chest. 1977;72:13-9.
27. Tynes B, Mason KN, Jennings AE, Bennett JE. Variant forms of pulmonary cryptococcosis. Ann Intern Med. 1968;69:1117-25.
28. Beyt Jr. BE, Waltman SR. Cryptococcal endophthalmitis after corneal transplantation. N Engl J Med. 1978;298:825-6.
29. Glaser JB, Garden A. Inoculation of cryptococcosis without transmission of the acquired immunodeficiency syndrome. N Engl J Med. 1985;313:266.
30. Kanj SS, Welty-Wolf K, Madden J, et al. Fungal infections in lung and heart-lung transplant recipients. Report of 9 cases and review of the literature. Medicine. 1996;75:142-56.
31. de Castro LE, Sarraf OA, Lally JM, Sandoval HP, Solomon KD, Vroman DT. Cryptococcus albidus keratitis after corneal transplantation. Cornea. 2005;24:882-3.
32. Nosanchuk JD, Shoham S, Fries BC, Shapiro DS, Levitz SM, Casadevall A. Evidence of zoonotic transmission of Cryptococcus neoformans from a pet cockatoo to an immunocompromised patient. Ann Intern Med. 2000;132:205-8.
33. Lagrou K, Van Eldere J, Keuleers S, et al. Zoonotic transmission of Cryptococcus neoformans from a magpie to an immunocompetent patient. J Intern Med. 2005;257:385-8.
34. Shrestha RK, Stoller JK, Honari G, Procop GW, Gordon SM. Pneumonia due to Cryptococcus neoformans in a patient receiving infliximab: Possible zoonotic transmission from a pet cockatiel. Respir Care. 2004;49:606-8.
35. Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis. 2001;33:690-9.
36. Vilchez RA, Irish W, Lacomis J, Costello P, Fung J, Kusne S. The clinical epidemiology of pulmonary cryptococcosis in non-AIDS patients at a tertiary care medical center. Medicine. 2001;80:308-12.
37. Sun HY, Wagener MM, Singh N. Cryptococcosis in solid-organ, hematopoietic stem cell, and tissue transplant recipients: evidencebased evolving trends. Clin Infect Dis. 2009;48:1566-76.
38. Kontoyiannis DP, Peitsch WK, Reddy BT, et al. Cryptococcosis in patients with cancer. Clin Infect Dis. 2001;32:e145-50.
39. Chayakulkeeree M, Perfect JR. Cryptococcosis. Infect Dis Clin N Am. 2006;20:507-44.
40. Hage CA, Wood KL, Winer-Muram HT, Wilson SJ, Sarosi G, Knox KS. Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy. Chest. 2003;124:2395-7.
41. Silveira FP, Husain S, Kwak EJ, et al. Cryptococcosis in liver and kidney transplant recipients receiving anti-thymocyte globulin or alemtuzumab. Transpl Infect Dis. 2007;9:22-7.
42. Peleg AY, Husain S, Kwak EJ, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis. 2007;44:204-12.
43. Munoz P, Giannella M, Valerio M, et al. Cryptococcal meningitis in a patient treated with infliximab. Diagn Microbiol Infect Dis. 2007;57:443-6.
44. Lewis JL, Rabinovich S. The wide spectrum of cryptococcal infections. Am J Med. 1972;53:315-22.
45. Dismukes WE, Cloud G, Gallis HA, et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med. 1987;317:334-41.
46. Zonios DI, Falloon J, Huang CY, Chaitt D, Bennett JE. Cryptococcosis and idiopathic CD4 lymphocytopenia. Medicine (Baltimore). 2007;86:78-92.
47. Duncan RA, von Reyn CF, Alliegro GM, Toossi Z, Sugar AM, Levitz SM. Idiopathic CD4+ T-lymphocytopenia - four patients with opportunistic infections and no evidence of HIV infection. N Engl J Med. 1993;328:393-8.
48. Currie BP, Casadevall A. Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin Infect Dis. 1994;19:1029-33.
49. Dismukes WE. Antifungal therapy: From amphotericin B to present. Trans Am Clin Climatol Assoc. 1993;104:166-77. discussion 77-9.
50. Dromer F, Mathoulin S, Dupont B, Laporte A, French Cryptococcosis Study Group. Epidemiology of cryptococcosis in France: A 9-year survey (1985-1993). Clin Infect Dis. 1996;23:82-90.
51. Dromer F, Mathoulin-Pelissier S, Fontanet A, Ronin O, Dupont B, Lortholary O. Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- And post-HAART eras. AIDS (London). 2004;18:555-62.
52. Mirza SA, Phelan M, Rimland D, et al. The changing epidemiology of cryptococcosis: An update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis. 2003;36:789-94.
53. Chen SC. Cryptococcosis in Australasia and the treatment of cryptococcal and other fungal infections with liposomal amphotericin B. J Antimicrob Chemother. 2002;49 Suppl 1:57-61.
54. Hakim JG, Gangaidzo IT, Heyderman RS, et al. Impact of HIV infection on meningitis in Harare, Zimbabwe: A prospective study of 406 predominantly adult patients. AIDS (London). 2000;14:1401-7.
55. Jarvis JN, Boulle A, Loyse A, et al. High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. AIDS (London). 2009;23:1182-3.
56. Heyderman RS, Gangaidzo IT, Hakim JG, et al. Cryptococcal meningitis in human immunodeficiency virus-infected patients in Harare, Zimbabwe. Clin Infect Dis. 1998;26:284-9.
57. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS (London). 2009;23:525-30.
58. Goldman D, Lee SC, Casadevall A. Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect Immun. 1994;62:4755-61.
59. Kwon-Chung KJ, Kozel TR, Edman JC, et al. Recent advances in biology and immunology of Cryptococcus neoformans. J Med Vet Mycol. 1992;30 Suppl 1:133-42.
60. Bolanos B, Mitchell TG. Phagocytosis of Cryptococcus neoformans by rat alveolar macrophages. J Med Vet Mycol. 1989;27: 203-17.
61. Harrison TS, Levitz SM. Mechanisms of impaired anticryptococcal activity of monocytes from donors infected with human immunodeficiency virus. J Infect Dis. 1997;176:537-40.
62. Levitz SM, Mathews HL, Murphy JW. Direct antimicrobial activity of T cells. Immunol Today. 1995;16:387-91.
63. Casadevall A. Antibody immunity and invasive fungal infections. Infect Immun. 1995;63:4211-8.
64. Lendvai N, Casadevall A, Liang Z, Goldman DL, Mukherjee J, Zuckier L. Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide. J Infect Dis. 1998;177:1647-59.
65. Rachini A, Pietrella D, Lupo P, et al. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect Immun. 2007;75:5085-94.
66. Buchanan KL, Murphy JW. What makes Cryptococcus neoformans a pathogen? Emerg Infect Dis. 1998;4:71-83.
67. Ma H, May RC. Virulence in Cryptococcus species. Adv Appl Microbiol. 2009;67:131-90.
68. Heitman J, Kozel T, Kwon-Chung J, Perfect J, Casadevall A, editors. Cryptococcus: From human pathogen to model yeast. Washington, DC: American Society for Microbiology Press; 2010.
69. Chang YC, Kwon-Chung KJ. Complementation of a capsuledeficient mutation of Cryptococcus neoformans restores its virulence. Mol Cell Biol. 1994;14:4912-9.
70. Guerrero A, Jain N, Goldman DL, Fries BC. Phenotypic switching in Cryptococcus neoformans. Microbiology. 2006;152:3-9.
71. Bulmer GS, Sans MD. Cryptococcus neoformans. 3. Inhibition of phagocytosis. J Bacteriol. 1968;95:5-8.
72. Levitz SM, Tabuni A, Kornfeld H, Reardon CC, Golenbock DT. Production of tumor necrosis factor alpha in human leukocytes stimulated by Cryptococcus neoformans. Infect Immun. 1994;62: 1975-81.
73. Collins HL, Bancroft GJ. Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses. Infect Immun. 1991;59:3883-8.
74. Kwon-Chung KJ, Polacheck I, Popkin TJ. Melanin-lacking mutants of Cryptococcus neoformans and their virulence for mice. J Bacteriol. 1982;150:1414-21.
75. Wang Y, Aisen P, Casadevall A. Cryptococcus neoformans melanin and virulence: Mechanism of action. Infect Immun. 1995;63: 3131-6.
76. Rittershaus PC, Kechichian TB, Allegood JC, et al. Glucosylceramide synthase is an essential regulator of pathogenicity of Cryptococcus neoformans. J Clin Invest. 2006;116:1651-9.
77. Garcia J, Shea J, Alvarez-Vasquez F, et al. Mathematical modeling of pathogenicity of Cryptococcus neoformans. Mol Syst Biol. 2008;4:183.
78. Visnegarwala F, Graviss EA, Lacke CE, et al. Acute respiratory failure associated with cryptococcosis in patients with AIDS: Analysis of predictive factors. Clin Infect Dis. 1998;27:1231-7.
79. Murray RJ, Becker P, Furth P, Criner GJ. Recovery from cryptococcemia and the adult respiratory distress syndrome in the acquired immunodeficiency syndrome. Chest. 1988;93:1304-6.
80. Chang WC, Tzao C, Hsu HH, et al. Pulmonary cryptococcosis: comparison of clinical and radiographic characteristics in immunocompetent and immunocompromised patients. Chest. 2006;129: 333-40.
81. Kerkering TM, Duma RJ, Shadomy S. The evolution of pulmonary cryptococcosis: clinical implications from a study of 41 patients with and without compromising host factors. Ann Intern Med. 1981;94:611-6.
82. Pappas PG. Therapy of cryptococcal meningitis in non-HIV-infected patients. Curr Infect Dis Rep. 2001;3:365-70.
83. Baddley JW, Perfect JR, Oster RA, et al. Pulmonary cryptococcosis in patients without HIV infection: Factors associated with disseminated disease. Eur J Clin Microbiol Infect Dis. 2008;27: 937-43.
84. Roebuck DJ, Fisher DA, Currie BJ. Cryptococcosis in HIV negative patients: Findings on chest radiography. Thorax. 1998;53:554-7.
85. Oliveira Fde M, Severo CB, Guazzelli LS, Severo LC. Cryptococcus gattii fungemia: report of a case with lung and brain lesions mimicking radiological features of malignancy. Rev Inst Med Trop São Paulo. 2007;49:263-5.
86. Speed B, Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis. 1995;21:28-34.
87. Khoury MB, Godwin JD, Ravin CE, Gallis HA, Halvorsen RA, Putman CE. Thoracic cryptococcosis: Immunologic competence and radiologic appearance. Am J Roentgenol. 1984;142:893-6.
88. Shirley RM, Baddley JW. Cryptococcal lung disease. Curr Opin Pulm Med. 2009;15:254-60.
89. Woodring JH, Ciporkin G, Lee C, Worm B, Woolley S. Pulmonary cryptococcosis. Semin Roentgenol. 1996;31:67-75.
90. Cameron ML, Bartlett JA, Gallis HA, Waskin HA. Manifestations of pulmonary cryptococcosis in patients with acquired immunodeficiency syndrome. Rev Infect Dis. 1991;13:64-7.
91. Meyohas MC, Roux P, Bollens D, et al. Pulmonary cryptococcosis: localized and disseminated infections in 27 patients with AIDS. Clin Infect Dis. 1995;21:628-33.
92. Saag MS, Powderly WG, Cloud GA, The NIAID Mycoses Study Group and the AIDS Clinical Trials Group, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDSassociated cryptococcal meningitis. N Engl J Med. 1992;326:83-9.
93. vanderHorst CM, Saag MS, Cloud GA, National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med. 1997;337:15-21.
94. Graybill JR, Sobel J, Saag M, The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. Clin Infect Dis. 2000;30: 47-54.
95. Pappas PG. Managing cryptococcal meningitis is about handling the pressure. Clin Infect Dis. 2005;40:480-2.
96. Bicanic T, Brouwer AE, Meintjes G, et al. Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS (London). 2009;23:701-6.
97. Fujita NK, Reynard M, Sapico FL, Guze LB, Edwards Jr. JE. Cryptococcal intracerebral mass lesions: The role of computed tomography and nonsurgical management. Ann Intern Med. 1981; 94:382-8.
98. Charlier C, Dromer F, Leveque C, et al. Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era. PloS. 2008;3:e1950.
99. Singh N, Lortholary O, Dromer F, et al. Central nervous system cryptococcosis in solid organ transplant recipients: clinical relevance of abnormal neuroimaging findings. Transplantation. 2008;86:647-51.
100. Mitchell DH, Sorrell TC, Allworth AM, et al. Cryptococcal disease of the CNS in immunocompetent hosts: Influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis. 1995;20:611-6.
101. Popovich MJ, Arthur RH, Helmer E. CT of intracranial cryptococcosis. Am J Roentgenol. 1990;154:603-6.
102. Park MK, Hospenthal DR, Bennett JE. Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting. Clin Infect Dis. 1999;28:629-33.
103. Liliang PC, Liang CL, Chang WN, Lu K, Lu CH. Use of ventriculoperitoneal shunts to treat uncontrollable intracranial hypertension in patients who have cryptococcal meningitis without hydrocephalus. Clin Infect Dis. 2002;34:E64-8.
104. Diamond RD, Bennett JE. Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann Intern Med. 1974;80:176-81.
105. Lu CH, Chang WN, Chang HW, Chuang YC. The prognostic factors of cryptococcal meningitis in HIV-negative patients. J Hosp Infect. 1999;42:313-20.
106. Powderly WG, Saag MS, Cloud GA, The NIAID AIDS Clinical Trials Group and Mycoses Study Group, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1992;326:793-8.
107. Powderly WG, Cloud GA, Dismukes WE, Saag MS. Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis. Clin Infect Dis. 1994;18:789-92.
108. Bicanic T, Wood R, Meintjes G, et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: A randomized trial. Clin Infect Dis. 2008;47: 123-30.
109. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis. 2001;33:641-7.
110. Baer S, Baddley JW, Gnann JW, Pappas PG. Cryptococcal disease presenting as necrotizing cellulitis in transplant recipients. Transpl Infect Dis 2009.
111. Pema K, Diaz J, Guerra LG, Nabhan D, Verghese A. Disseminated cutaneous cryptococcosis. Comparison of clinical manifestations in the pre-AIDS and AIDS eras. Arch Intern Med. 1994;154: 1032-4.
112. Anderson DJ, Schmidt C, Goodman J, Pomeroy C. Cryptococcal disease presenting as cellulitis. Clin Infect Dis. 1992;14:666-72.
113. Casadevall A, Mukherjee J, Yuan R, Perfect J. Management of injuries caused by Cryptococcus neoformans-contaminated needles. Clin Infect Dis. 1994;19:951-3.
114. Neuville S, Dromer F, Morin O, Dupont B, Ronin O, Lortholary O. Primary cutaneous cryptococcosis: A distinct clinical entity. Clin Infect Dis. 2003;36:337-47.
115. Behrman RE, Masci JR, Nicholas P. Cryptococcal skeletal infections: case report and review. Rev Infect Dis. 1990;12:181-90.
116. Nottebart HC, McGehee RF, Utz JP. Cryptococcus neoformans osteomyelitis: case report of two patients. Sabouraudia. 1974;12: 127-32.
117. Stead KJ, Klugman KP, Painter ML, Koornhof HJ. Septic arthritis due to Cryptococcus neoformans. J Infect. 1988;17:139-45.
118. Perfect JR. Cryptococcosis. Infect Dis Clin N Am. 1989;3:77-102.
119. Braman RT. Cryptococcosis (torulosis) of prostate. Urology. 1981;17:284-5.
120. Crump JR, Elner SG, Elner VM, Kauffman CA. Cryptococcal endophthalmitis: case report and review. Clin Infect Dis. 1992;14: 1069-73.
121. Leavitt AD, Kauffman CA. Cryptococcal aortitis. Am J Med. 1988;85:108-10.
122. Staib F, Seibold M, L'Age M, et al. Cryptococcus neoformans in the seminal fluid of an AIDS patient. A contribution to the clinical course of cryptococcosis. Mycoses. 1989;32:171-80.
123. Larsen RA, Bozzette S, McCutchan JA, Chiu J, Leal MA, Richman DD, et al. Persistent Cryptococcus neoformans infection of the prostate after successful treatment of meningitis. Ann Intern Med. 1989;111:125-8.
124. Bicanic T, Meintjes G, Rebe K, et al. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: A prospective study. J Acquir Immune Defic Syndr. 2009;51: 130-4.
125. Lortholary O, Fontanet A, Memain N, Martin A, Sitbon K, Dromer F. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS (London). 2005;19:1043-9.
126. Shelburne 3rd SA, Darcourt J, White Jr. AC, et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40:1049-52.
127. Singh N, Lortholary O, Alexander BD, et al. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis. 2005;40:1756-61.
128. Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS. 2005;19:399-406.
129. Singh N, Dromer F, Perfect JR, Lortholary O. Cryptococcosis in solid organ transplant recipients: current state of the science. Clin Infect Dis. 2008;47:1321-7.
130. Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med. 1979;301:126-31.
131. Aberg JA, Mundy LM, Powderly WG. Pulmonary cryptococcosis in patients without HIV infection. Chest. 1999;115:734-40.
132. Campbell CK, Payne AL, Teall AJ, Brownell A, MacKenzie DW. Cryptococcal latex antigen test positive in patient with Trichosporon beigelii infection. Lancet. 1985;2(8445):43-4.
133. Tarrand JJ, Guillot C, Wenglar M, Jackson J, Lajeunesse JD, Rolston KV. Clinical comparison of the resin-containing BACTEC 26 Plus and the Isolator 10 blood culturing systems. J Clin Microbiol. 1991;29:2245-9.
134. Reference method for broth dilution antifungal susceptibility testing of yeasts: Approved standard, 3rd edn., M23-A3. Wayne: Clinical Laboratory Standards Institute, 2008.
135. Brandt ME, Pfaller MA, Hajjeh RA, et al. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob Agents Chemother. 2001;45:3065-9.
136. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol. 2009;47:117-23.
137. Torres-Rodriguez JM, Alvarado-Ramirez E, Murciano F, Sellart M. MICs and minimum fungicidal concentrations of posaconazole, voriconazole and fluconazole for Cryptococcus neoformans and Cryptococcus gattii. J Antimicrob Chemother. 2008;62:205-6.
138. Bartizal K, Gill CJ, Abruzzo GK, et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743, 872). Antimicrob Agents Chemother. 1997;41:2326-32.
139. Aller AI, Martin-Mazuelos E, Lozano F, et al. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother. 2000;44:1544-8.
140. Armengou A, Porcar C, Mascaro J, Garcia-Bragado F. Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis. 1996;23:1337-8.
141. Witt MD, Lewis RJ, Larsen RA, et al. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: The role of antifungal susceptibility testing. Clin Infect Dis. 1996;22:322-8.
142. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Disease Society of America. Clin Infect Dis. 2010;50:291-322.
143. Hospenthal DR, Bennett JE. Flucytosine monotherapy for cryptococcosis. Clin Infect Dis. 1998;27:260-4.
144. Harrison TS. Amphotericin B plus fluconazole for HIV-associated cryptococcal meningitis. Clin Infect Dis. 2009;48:1784-6.
145. Pappas PG, Chetchotisakd P, Larsen RA, et al. A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis. 2009;48:1775-83.
146. Dromer F, Mathoulin S, Dupont B, Brugiere O, Letenneur L, French Cryptococcosis Study Group. Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. Clin Infect Dis. 1996;22 Suppl 2:S154-60.
147. Nadrous HF, Antonios VS, Terrell CL, Ryu JH. Pulmonary cryptococcosis in nonimmunocompromised patients. Chest. 2003;124: 2143-7.
148. Jarvis JN, Harrison TS. Pulmonary cryptococcosis. Semin Respir Crit Care Med. 2008;29:141-50.
149. Yamaguchi H, Ikemoto H, Watanabe K, Ito A, Hara K, Kohno S. Fluconazole monotherapy for cryptococcosis in non-AIDS patients. Eur J Clin Microbiol Infect Dis. 1996;15:787-92.
150. Denning DW, Tucker RM, Hanson LH, Hamilton JR, Stevens DA. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Intern Med. 1989;149:2301-8.
151. Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis. 2006;42:1726-34.
152. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36:1122-31.
153. Sharkey PK, Graybill JR, Johnson ES, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1996;22:315-21.
154. Coker RJ, Viviani M, Gazzard BG, et al. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS (London, England). 1993;7:829-35.
155. Leenders AC, Reiss P, Portegies P, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS (London). 1997;11:1463-71.
156. Hammerman KJ, Powell KE, Christianson CS, et al. Pulmonary cryptococcosis: clinical forms and treatment. A Center for Disease Control Cooperative Mycoses study. Am Rev Respir Dis. 1973;108:1116-23.
157. Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis. 2001;7:375-81.
158. Hospenthal DR, Bennett JE. Persistence of cryptococcomas on neuroimaging. Clin Infect Dis. 2000;31:1303-6.
159. Larsen RA, Bozzette SA, Jones BE, et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1994;19:741-5.
160. Mayanja-Kizza H, Oishi K, Mitarai S, et al. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin Infect Dis. 1998;26:1362-6.
161. Menichetti F, Fiorio M, Tosti A, et al. High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1996;22:838-40.
162. Haubrich RH, Haghighat D, Bozzette SA, Tilles J, McCutchan JA, The California Collaborative Treatment Group. High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. J Infect Dis. 1994;170:238-42.
163. de Gans J, Portegies P, Tiessens G, et al. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS (London). 1992;6:185-90.
164. Bozzette SA, Larsen RA, Chiu J, California Collaborative Treatment Group, et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. N Engl J Med. 1991;324:580-4.
165. Saag MS, Cloud GA, Graybill JR, National Institute of Allergy and Infectious Diseases Mycoses Study Group, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDSassociated cryptococcal meningitis. Clin Infect Dis. 1999;28:291-6.
166. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR. 2009;58:1-207.
167. Mussini C, Pezzotti P, Miro JM, et al. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: An international observational study. Clin Infect Dis. 2004;38:565-71.
168. Vibhagool A, Sungkanuparph S, Mootsikapun P, et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: A prospective, multicenter, randomized study. Clin Infect Dis. 2003;36:1329-31.
169. Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviralnaive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis. 2007;45:76-80.
170. Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med. 1989;321:794-9.
171. Larsen RA, Leal MA, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann Intern Med. 1990;113:183-7.
172. Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: A randomised trial. Lancet. 2004;363:1764-7.
173. Dromer F, Bernede-Bauduin C, Guillemot D, Lortholary O. Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PloS. 2008;3:2870.
174. Baddour LM, Perfect JR, Ostrosky-Zeichner L. Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. Clin Infect Dis. 2005;40 Suppl 6:S409-13.
175. Longley N, Muzoora C, Taseera K, et al. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis. 2008;47:1556-61.
176. Aberg JA, Price RW, Heeren DM, Bredt B. A pilot study of the discontinuation of antifungal therapy for disseminated cryptococcal disease in patients with acquired immunodeficiency syndrome, following immunologic response to antiretroviral therapy. J Infect Dis. 2002;185:1179-82.
177. Zolopa A, Andersen J, Komarow L, et al. Immediate vs. deferred ART in the setting of a randomized strategy trial ACTG A5164. 15th Conference on Retroviruses and Opportunistic Infections. February, 2008. Boston. Abstract 142.
178. Newton PN, le Thai H, Tip NQ, et al. A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin Infect Dis. 2002;35:769-72.
179. McKinsey DS, Wheat LJ, Cloud GA, National Institute of Allergy and Infectious Diseases Mycoses Study Group, et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebocontrolled, double-blind study. Clin Infect Dis. 1999;28: 1049-56.
180. Powderly WG, Finkelstein D, Feinberg J, NIAID AIDS Clinical Trials Group, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med. 1995;332:700-5.
181. Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, Harrison TS. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis. 2009;48:856-62.
182. Tassie JM, Pepper L, Fogg C, et al. Systematic screening of cryptococcal antigenemia in HIV-positive adults in Uganda. J Acquir Immune Defic Syndr. 2003;33:411-2.
183. Nelson MR, Bower M, Smith D, Reed C, Shanson D, Gazzard B. The value of serum cryptococcal antigen in the diagnosis of cryptococcal infection in patients infected with the human immunodeficiency virus. J Infect. 1990;21:175-81.
184. Desmet P, Kayembe KD, De Vroey C. The value of cryptococcal serum antigen screening among HIV-positive/AIDS patients in Kinshasa, Zaire. AIDS (London). 1989;3:77-8.
185. Liechty CA, Solberg P, Were W, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health. 2007;12:929-35.
186. Micol R, Lortholary O, Sar B, et al. Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr. 2007;45:555-9.
187. French N, Gray K, Watera C, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS (London). 2002; 16:1031-8.